No Data
No Data
Tryptamine Therapeutics Concludes Phase 2a Clinical Study for Pain and Tenderness Drug; Shares Rise 11%
Tryptamine Therapeutics (ASX:TYP) concluded a phase 2a clinical study of its intravenous-infused psilocin formulation for fibromyalgia, in collaboration with the University of Michigan, the clinical-
Tryptamine Therapeutics Achieves Milestone of World's First IV-infused Psilocin Dosing
Recently-listed biotech company Tryptamine Therapeutics (ASX: TYP) has successfully completed the world’s first dosing of a patient with intravenous (IV)-infused psilocin (TRP-8803) in South Australia.
Tryptamine Therapeutics Completes Maiden Dosing of IV Psilocin – a Global First
Tryptamine Therapeutics (ASX:TYP) has finished dosing the first patient with psilocin using an IV drip in a global first.
Tryptamine Therapeutics Partners With Lucid Health to Advance TRP-8803's Product Registration in Australia
Tryptamine Therapeutics (ASX:TYP) is advancing the product registration and reimbursement strategy in Australia for its neuropsychiatric disorder treatment TRP-8803 by appointing advisory group Lucid
Tryptamine Therapeutics Begins to Trade on ASX; Shares Surge 118%
Shares of clinical-stage biotechnology company Tryptamine Therapeutics (ASX:TYP) began to trade on the Australian Securities Exchange (ASX) on Wednesday, under the ticker code TYP, the company said in
No Data